Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300
degrader programs
Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT
CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that
treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will
review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR)
Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.
Conference Call Details
Tuesday, April 9, at 5 p.m. ET / 2 p.m. PT
Toll Free: 1-877-704-4453
International: 1-201-389-0920
Conference ID: 13745314
Webcast: Foghorn Events and Presentations
About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary
scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing
multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and
LinkedIn.
About FHD-286
FHD-286 is a highly potent, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly
similar proteins that are the ATPases, or the catalytic engines, of the BAF complex, one of the key regulators within the chromatin regulatory system. In preclinical studies, FHD-286 has shown
anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
About AML
Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic
mutations. It is diagnosed in about 20,000 people every year in the United States.